Compare Cassava Sciences Inc (FLNA) vs New York Times Co (NYT) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Cassava Sciences Inc vs New York Times Co — how do they compare? Cassava Sciences Inc trades at $0.83 (market cap $39.40M), while New York Times Co trades at $66.52 (market cap $10.74B). The key difference: New York Times Co is far larger — about 272.6× Cassava Sciences Inc's market cap, and New York Times Co pays a 1.38% dividend while Cassava Sciences Inc pays none. Which is the better fit depends on your goals — on Pluang, investors hold Cassava Sciences Inc for 37 Days and New York Times Co for 81 Days on average.
| FLNA | NYT | |
|---|---|---|
Market Cap | $39.40M | $10.74B |
Volume | 759,018 | 2,096,352 |
Sector | Health | Media |
52-Week High | $4.64 | $85.86 |
52-Week Low | $0.68 | $54.66 |
Typical Hold Time | 37 Days | 81 Days |
Enterprise Value | -$43.28M | $10.14B |
Dividend Yield | — | 1.38% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Filana Therapeutics (FLNA) trades at $0.82, down 6.77% today, amid bearish technical signals but with positive fundamental catalysts. The company shows improving quarterly EPS beats and a favorable EV/EBITDA of 1.03, though it remains unprofitable with negative cash flow. Recent FDA clearance for its epilepsy drug trial has generated optimism, reflected in strong analyst buy ratings (67% consensus).
The outlook balances clinical progress against financial strain. The FDA hold lift on simufilam provides a clear near-term catalyst for Phase 2a trials starting in 2027, supporting the bullish analyst view. However, high cash burn (-$33M net CF in 2025) and lack of revenue pose significant risks to sustainability, requiring careful monitoring of funding and trial milestones.
The New York Times Company (NYT) trades at $64.90, up 1.3% with a bearish technical signal despite strong fundamental performance. Recent earnings beats and consistent revenue growth to $2.82 billion in 2025 highlight operational strength, though a shareholder lawsuit and AI copyright disputes present headwinds. Analyst consensus is mixed with a $84 price target suggesting 29% upside from current levels.
The stock offers value through earnings growth and dividend yield, but faces sentiment pressure from legal challenges and technical indicators. Key risks include litigation outcomes and competitive pressures in digital media, while institutional ownership trends and positive cash flow generation support the investment case for patient investors.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
About Cassava Sciences Inc
Cassava Sciences Inc is a clinical-stage biotechnology company engaged in developing a scientific approach for the treatment and detection of Alzheimer's disease. Its therapeutic product candidate is called simufilam, and it is a novel treatment for Alzheimer's disease
Read more on FLNA →About New York Times Co
New York Times Co is an American media company known for publishing its flagship newspaper, The New York Times. The company also operates the International New York Times newspaper, as well as digital properties such as nytimes and various smartphone applications. Circulation of The New York Times is the source of revenue for the company, followed by print and digital advertising and its paid digital-only subscription to The New York Times. The company has a daily print circulation of over 500,000 and 1,000,000 on Sundays. The source of growth for The New York Times is its digital subscription service, which has over 1,000,000 paid users.
Read more on NYT →
